Filing of DMF in the US, EU, and India, and its comparative review
A Drug Master File (DMF) covers all comprehensive, accurate, and precise information about Active Pharmaceutical Ingredient (API) or Finished Product Dosage Form (FP). It is a confidential document that contains complete, factual, and correct information about the active pharmaceutical ingredient and drug product's chemistry, manufacture, stability, purity, impurity profile, packaging, and the cGMP (Current Good Manufacturing Practices) status of any human drug product. When a DMF is filed, it allows a company to safeguard its intellectual property from its partner while complying with regulatory requirements when its process details are disclosed. There is no legalised or regulatory requirement to file a DMF. A DMF comprises of two parts: (a) the Applicant's Part (Open Part), which contains all the information to assess the quality that the license-holder requires and submit a license or amendment application; and (b) the Restricted Part (Closed Part), which contains confidential information about the manufacturing procedure which is only disclosed to the authorities.
A DMF can be used by a holder who establishes the file or by one or more parties to support their files or applications.
The present study is to brief an overview of DMF filing in different countries, which are the USA, Europe, and India. It also gives information on regulatory requirements of Drug Master Files by Food and Drug Administration (USA), European Medicines Agency (Europe), and Central Drug and Standard Control Organization (India) and their comparison.
2. Gupta R. Inside Story for Review of DMF And Dossiers by Regulatory Authorities [Internet]. FDA; 2012 [cited 2020 Oct 18]. Available from:
3. Peter J. Schmitt. Drug Master Files Global Perspectives [Internet]. slideserve.com; 2011 [cited 2020 Dec 23]. Available from: https://www.slideserve.com/quintessa-holden/drug-master-files-global-perspectives
4. Agarwal P, Badjatya JK. DMF FILING IN US, EUROPE AND CANADA. Int J Drug Reg Affairs [Internet]. 2018 Feb 13 [cited 2021 Jan 27];3(4):9-17. Available from: http://ijdra.com/index.php/journal/article/view/172
5. Yehaskel A. An Overview of Drug Master Files [Internet] Pharm Regul Aff Open Access. 2018 [cited 2021 Jan 23]; 07(01). Available from:
6. Kanti SPY, Jain N, Chandra A, Shukla VK. Filing of DMF in US, Canada & Europe. Int J Drug Reg Affairs [Internet]. 2019 Mar 16 [cited 2021 Jan 27];7(1):6-12. Available from:
7. Gurram I, Kavitha MVS, Reddy N, Nagabhushanam MV. Drug Master File Filing in US, Europe, Canada and Australia J Pharm Res. [Internet]. 2017 Feb 16 [cited 2020 Nov 26]. Available from:
8. K. Arshad Ahmed Khan. Drug Master File submissions [Internet]. slideshare.net; 2018 Aug 17 [cited 2021 Jan 23]. Available from:
9. Nizamuddin. What is a Drug Master File (DMF)? [Internet]. Freyr - Global Regulatory Solutions and Services Company; 2019 [cited 2021 Jan 23]. Available from:
10. Shravya K, Swathi P, et al. Regulatory Dossiers of ASEM Countries. International. Journal of pharmaceutical sciences and research [Internet]. 2017 Aug 1 [cited 2021 Jan 20]. Available from:
11. Guideline for Drug Master Files (DMF), CDER [Internet]. FDA; 2015 Oct 11 [cited 2020 Dec 19]. Available from: https://www.fda.gov/drugs/drug-master-files-dmfs/guideline-drug-master-files-dmf
12. Battaglino G. The European Drug Master File. Sage journals [Internet]. 2011 Oct 01 [cited 2020 Nov 14];27(4):1261–5. Available from:
13. Dinesh K. Difference European drug master file & US drug master file [Internet]. FDA; 2016 May 20 [cited 2021 Jan 23]. Available from:
14. Guideline on Active Substance Master File Procedure [Internet]. European Medicines Agency; 2013 May 31 [cited 2020 Nov 01]. Available from:
15. Overview on DMF/CEP - Need of Regulatory Submission. Freyr Blog [Internet]. Freyr - Global Regulatory Solutions and Services Company; 2012 Feb 13 [cited 2021 Jan 23]. Available from:
16. Maki Matsuhama, Tomoko Takishita, et al. Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence [Internet]. Research Gate; 2016 Aug 5 [cited 2020 Nov 23]. Available from:
17. Kumar P, Mangla B, Singh S, Rana A. Drug Master File: Global Regulatory Issues and Challenges European Journal of Biomedical and Pharmaceutical sciences [Internet]. researchgate.net; 2017 Dec 17 [cited 2020 Dec 20]. Available from:
18. Indian firms top DMF filing with US FDA [Internet]. Financial Express. 2016 May [cited 2021 Jan 23]. Available from:
19. DMF submissions in 2019: India maintains bulk drug supply supremacy to US [Internet]. Team PharmaCompass; 2020 Jan 23 [cited 2021 Jan 23]. Available from:
20. DMF submissions in 2020: Industry sustains its filing momentum [Internet]. PharmaCompass.com; 2020 Jan 23 [cited 2021 Jan 23]. Available from:
21. Drug Master File (DMF) Consultant - US FDA [Internet]. MedDeviceCorp; 2020 May 19 [cited 2021 Jan 23]. Available from:
22. ANDA and DMF Filing Solution for a Pharma Client [Internet]. Cybage; 2019 Sep 24 [cited 2021 Jan 23]. Available from:
23. Case Study. Pharmaceutical Consultants India [Internet]. Perfect Pharmaceutical Consultants; 2020 [cited 2021 Jan 23]. Available from:
24. Szűts A, Láng P, Ambrus R, Kiss L, Deli MA, Szabó-Révész P. Applicability of sucrose laurate as surfactant in solid dispersions prepared by melt technology. Int J Pharm. [Internet]. 2011 May 30 [cited 2020 Dec 18]; 410(1–2):107–10. Available from:
25. Case Study. eCTD submissions for global DMF portfolio [Internet]. Pharmalex; 2019 May 24 [cited 2021 Jan 23]. Available from:
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM